NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), today announced the closing of its previously announced securities purchase ...

Why Clinicians Are Rethinking Hand, Foot, and Mouth Disease

Clinicians must adapt to the new reality of HFMD, as emerging strains drive serious complications and challenge old ...

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

Presentations at Association for Molecular Pathology 2025 Annual Meeting Spotlight Clinical Impact of Delve Bio’s Metagenomic Sequencing Test for Improving CNS Diagnosis

Presentations at AMP 2025 show utility of Delve Detect for diagnosing complex CNS infections, such as co-infection and culture-negative presentations ...
Onlymyhealth on MSN

Chickenpox Recovery: What To Expect During Each Stage

Wondering how long it takes to recover from chickenpox Read ahead to know as an expert explains each stage from first ...